Cefditoren also known as cefditoren pivoxil (trade names Zostom-O, Meiact, and Spectracef) is a broad-spectrum antibiotic, taken by mouth to treat pneumonia and other infections. It is a third-generation oral cephalosporin with a broad spectrum of activity against bacterial pathogens, including both Gram-positive and Gram-negative bacteria, and it is effective against some antibiotic-resistant bacteria because it is not susceptible to hydrolysis by many common beta-lactamases. The United States Food and Drug Administration approved cefditoren pivoxil for adults and adolescents (12 years of age or older) in 2001. In 2018 Zuventus Healthcare received approval for cefditoren pivoxil dry powder for suspension (100 mg / 5mL) for the treatment of mild to moderate infection in children (2 months to 12 years of age) which are caused by susceptible strains of the designated microorganisms.Cefditoren pivoxil may also reduce lung inflammation and epithelial damage by a non-bactericidal mechanism. It was patented in 1984 and approved for medical use in 1994. Structure
Like other cephalosporins, cefditoren has a β-lactam ring at the 7 position of cephalosporin ring that is responsible for its inhibitory action on bacterial cell wall synthesis. In addition to the cephem nucleus common to all cephalosporins, cefditoren has an aminothiazole group that enhances its activity against Gram-negative organisms, a methylthiazole group that enhances its activity against Gram-positive organisms, a methoxyimino group that gives it stability against β-lactamases, and a pivoxil ester group that enhances oral bioavailability. Antimicrobial activity
The spectrum of cefditoren includes both Gram-positive and Gram-negative bacterial species.
Traumatic alopecia is a cutaneous condition that results from the forceful pulling out of the scalp hair. See also
Traction alopecia
List of cutaneous conditions


== References ==